OÊı·ÏÌÔÏÔÁ›· - Πανελλήνια Οφθαλμολογική Εταιρεία

‡ÁÎÚÈÛË Ù˘ 24ˆÚ˘ ÂÓ‰ÔÊı¿ÏÌÈ·˜ apple›ÂÛ˘ ÌÂÏ·Ù·ÓÔappleÚfiÛÙË ‹ Ì ÙÔÓ Û˘Ó‰˘·ÛÌfi ÙÈÌÔÏfiÏ˘-ÓÙÔÚ˙ÔÏ·Ì›‰Ë˜ ˆ˜ appleÚÒÙ˘ ıÂÚ·apple¢ÙÈ΋˜ÂappleÈÏÔÁ‹˜ ÛÙÔ appleÚˆÙÔapple·ı¤˜ ÁÏ·‡ÎˆÌ·∞.-°.. ∫ÒÓÛÙ·˜1, . ·apple·apple¿ÓÔ˜2, . ª·ÏÔ‡Ù·˜1, ∞.Ã. ª·ÏÙ¤˙Ô˜1,π. Δ¤ÚÛ˘1, ¢. ÃÔ˘ÏÈ¿Ú·, 1 W.C. Stewart 324-hour comparison of latanorpost 0.005% versus the timolol/dorzolamide fixedcombination as first line therapy in primary open-angle glaucomaA.-G.P. Konstas, P. Papapanos, S. Maloutas, A.H. Maltezos, I. Tersis, D. Houliara, W.C. StewartÎÔapplefi˜: ˘ÁÎÚÈÙÈ΋ ÌÂϤÙË Ù˘ ·appleoÙÂÏÂÛÌ·ÙÈÎfiÙËÙ·˜ ηȷÛÊ¿ÏÂÈ·˜ Ù˘ ¯oÚ‹ÁËÛ˘ Ï·Ù·ÓoappleÚfiÛÙ˘ 0,005% Ì›· Êo-Ú¿ ÙËÓ Ë̤ڷ Î·È Ùo˘ ÛÙ·ıÂÚo‡ Û˘Ó‰˘·ÛÌo‡ ÙÈÌoÏfiÏ˘0,5% - ÓÙoÚ˙oÏ·Ì›‰Ë˜ 2% ‰‡o ÊoÚ¤˜ ÙËÓ Ë̤ڷ, Û ·ÛıÂ-Ó›˜ Ì appleÚˆÙoapple·ı¤˜ ÁÏ·‡ÎˆÌ· ·ÓoÈÎÙ‹˜ ÁˆÓ›·˜ (°∞°) ‹oÊı·ÏÌÈ΋ ˘appleÂÚÙoÓ›·. ∞ÛıÂÓ›˜-̤ıo‰oÈ: ∏ ÌÂϤÙË ‰ÈÂÍ‹-¯ıË Û ‰‡o ΤÓÙÚ·. ∂appleÈϤ¯ıËÎ·Ó Ù˘¯·›· 34 ·ÛıÂÓ›˜ oÈ o-appleo›oÈ ˘appleo‚Ï‹ıËÎ·Ó ÂÓ·ÏÏ¿Í ÛÙË Û˘ÁÎÚÈÙÈ΋ ÌÂϤÙË, ÂÊ·Ú-Ìfi˙oÓÙ·˜ ÙËÓ ·appleÏ‹ Ù˘ÊÏ‹ ̤ıo‰o. ∏ ÂÎÙ›ÌËÛË Ù˘ 24ˆÚ˘ÂÓ‰oÊı¿ÏÌÈ·˜ apple›ÂÛ˘ (∂O) ¤ÁÈÓ Ì 6 ÌÂÙÚ‹ÛÂȘ ÛÙȘ Ò-Ú˜: 02:00, 06:00, 10:00, 14:00, 18:00 Î·È 22:00. ∞appleoÙÂϤ-ÛÌ·Ù·: ΔË ÌÂϤÙË oÏoÎÏ‹ÚˆÛ·Ó 33 ·ÛıÂÓ›˜. ªÂÙ¿ ·applefi 6‚‰oÌ¿‰Â˜ ıÂÚ·apple›·˜, Ë Ì¤ÛË 24ˆÚË ∂O ‹Ù·Ó 15,9±2,3mmHg Ì ϷٷÓoappleÚfiÛÙË, Î·È 15,3±2,0 mmHg Ì ÙoÓ Û˘Ó-‰˘·ÛÌfi (p=0,05). ÃÚoÓÈο ·ÓÙ›ÛÙoȯ˜ ÌÂÙÚ‹ÛÂȘ Ù˘ ∂O‰ÂÓ apple·Úo˘Û›·Û·Ó ÛÙ·ÙÈÛÙÈο ÛËÌ·ÓÙÈ΋ ‰È·ÊoÚ¿ ÌÂÙ·Í‡ÙˆÓ ‰‡o oÌ¿‰ˆÓ, ÂÎÙfi˜ ·applefi ÙË Ì¤ÙÚËÛË ÙˆÓ 22:00, fiappleo˘ Ë∂O Ì ÙoÓ Û˘Ó‰˘·ÛÌfi ‹Ù·Ó 14,6±2,7 mmHg ÂÓÒ Ì ÙËÏ·Ù·ÓoappleÚfiÛÙË ‹Ù·Ó 16,6±3,1 mmHg (p0,05), ÂÎÙfi˜ ·applefi ÙËÓ appleÈÎÚ‹ Á‡-ÛË appleo˘ ‹Ù·Ó Û˘¯ÓfiÙÂÚË Ì ÙoÓ Û˘Ó‰˘·ÛÌfi (n=9) apple·Ú¿ ÌÂÙË Ï·Ù·ÓoappleÚfiÛÙË (n =0), (p=0,009). ˘ÌappleÂÚ¿ÛÌ·Ù·: ∞applefiÙË ÌÂϤÙË appleÚo·appleÙÂÈ fiÙÈ o ¤ÏÂÁ¯o˜ Ù˘ 24ˆÚ˘ ÂÓ‰oÊı¿Ï-ÌÈ·˜ apple›ÂÛ˘ ·ÛıÂÓÒÓ Ì °∞° ‹ ˘appleÂÚÙoÓ›· Â›Ó·È oÚȷο η-χÙÂÚo˜ Ì ÙoÓ ¤ÙoÈÌo Û˘Ó‰˘·ÛÌfi ÙÈÌoÏfiÏ˘-ÓÙoÚ˙oÏ·Ì›-‰Ë˜ Û ۇÁÎÚÈÛË Ì ÙË Ï·Ù·ÓoappleÚfiÛÙË.Purpose: To evaluate the efficacy and safety of latanoprost0.005% given every evening versus the timolol 0.5%/ dorzolamide2% fixed combination (Cosopt) given twice daily inprimary open-angle glaucoma (POAG) and ocular hypertensivepatients. Design: A single-masked, two center,crossover comparison with two six-week treatment periodsfollowing at least a three-week medicine free period. Diurnalcurve intraocular pressures (IOP) were taken at 02:00,06:00, 10:00, 14:00, 18:00 and 22:00 hours. Thirty-four subjectswith POAG or ocular hypertension were enrolled. Latanoprost0.005% given every evening and the fixed combinationtwice daily. Results: Thirty-three patients completedthe study. Following six weeks of treatment the diurnal IOPfor latanoprost was 15.9±2.3 mmHg and for the fixed combinationwas 15.3±2.0 mmHg (p=0.05). Individual time pointsfor IOP pressure were statistically equal between groupsexcept at the 22:00 time point when the fixed combinationwas 14.6±2.7 mmHg and latanoprost was 16.6±3.1 mmHg(p0.05) e-xcept bitter taste was found more frequently with the combination(n=9) than latanoprost (n =0); (p=0.009). Conclusion:This study indicates that the 24-hour diurnal IOP is improvedslightly with the timolol maleate/dorzolamide fixedcombination compared to latanoprost in POAG and ocularhypertensive patients.1·ÓÂappleÈÛÙËÌȷ΋ OÊı·ÏÌÔÏÔÁÈ΋ KÏÈÓÈ΋ AXEA, £ÂÛÛ·ÏÔÓ›ÎË2°.N.N. KÔÚ›ÓıÔ˘, KfiÚÈıÓÔ˜, 3 University of Shouth Carolina, Columbia, S.C., U.S.A.OÊı·ÏÌÔÏÔÁ›·, 14, 2 : 171 - 176, 2002 171